maxwellt/fedgrantsembedded huggingface dataset:
NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-20 | Closing date: 2025-01-07
Cost sharing or matching requirement: No

The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
Agency: National Institutes of Health
Posted: 2022-01-21 | Closing date: 2024-12-04
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and Small Disadvantaged small business are encouraged to apply.

Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-21 | Closing date: 2025-05-07
Cost sharing or matching requirement: No

The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
Agency: National Institutes of Health
Posted: 2022-01-21 | Closing date: 2025-05-07
Award ceiling: 40000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33  Clinical Trials Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-12-20
Cost sharing or matching requirement: No

This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-12-20
Award ceiling: 300000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
NIMH Instrumentation Program (S10 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-10-09
Cost sharing or matching requirement: No

Reissue of RFA-MH-20-555. The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or a group of components to create an instrument that is not commercially available. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Catalyze: Product Definition  Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation  (R33 - Clinical Trials Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-12-20
Award ceiling: 250000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Catalyze: Product Definition  Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-12-20
Cost sharing or matching requirement: No

This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-24 | Closing date: 2024-12-20
Award ceiling: 350000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
NHGRI Short Courses for Genomics-Related Research Education (R25 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-01-31 | Closing date: 2025-01-25
Award ceiling: 150000
Cost sharing or matching requirement: No

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development. Proposed short courses are expected to facilitate the development of a cadre of investigators with the requisite research skills to advance the mission of NHGRI. Applications are encouraged that propose innovative, advanced-level courses that are intended to disseminate new knowledge, analyses, methods and techniques related to the scientific, medical, ethial, social and/or legal areas of genomics research.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research  (U24 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-03 | Closing date: 2024-09-25
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?support?large-scale, complex research programs focused on?Alzheimers disease (AD) and?Alzheimers disease-related dementias (ADRD).?It is anticipated that such programs will likely involve a team of investigators within a single institution or a consortium of?institutions?and?align with one or more?AD/ADRD implementation research milestones?supporting the?research goals of the??National Plan to Address Alzheimers and Related Dementias.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-04 | Closing date: 2025-01-07
Cost sharing or matching requirement: No

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available a www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
Agency: National Institutes of Health
Posted: 2022-02-08 | Closing date: 2024-12-09
Cost sharing or matching requirement: No

This is a reissue to correct a few errors and omissions. This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
Agency: National Institutes of Health
Posted: 2022-02-08 | Closing date: 2024-12-09
Cost sharing or matching requirement: No

This is a reissue to correct errors and omissions. This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required)
Agency: National Institutes of Health
Posted: 2022-02-11 | Closing date: 2025-01-07
Cost sharing or matching requirement: No

The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences to enhance the diversity of well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-11 | Closing date: 2025-01-07
Cost sharing or matching requirement: No

The purpose of the NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to enhance the diversity of well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Solar, Heliospheric, and INterplanetary Environment
Agency: National Science Foundation
Posted: 2022-02-11 | Closing date: 2024-10-07
Estimated total program funding: 3000000
Award ceiling: 200000
Award floor: 120000
Expected number of awards: 15
Cost sharing or matching requirement: No

Solar, Heliospheric, and Interplanetary Environment (SHINE) is a broad-based research program supportingenhanced understanding of and predictive capabilities for the processes by which energy in the form of magnetic fields and particles are produced by the Sun and/or accelerated in interplanetary space and on the mechanisms by which these fields and particles are transported to the Earth through the inner heliosphere.Broad-based, grass-roots associations such as SHINE have developed to focus community effort on these scientific questions. Proposals are solicited for research directly related to topics under consideration and discussion at community workshops organized by SHINE under focused topic areas indicated in the program description. Information on the current activities of SHINE may be found at the following web site: http://www.shinecon.org
Algorithms for Modern Power Systems
Agency: National Science Foundation
Posted: 2022-02-11 | Closing date: 2025-02-10
Estimated total program funding: 2000000
Award floor: 300000
Expected number of awards: 10
Cost sharing or matching requirement: No

The Algorithms for Modern Power Systems (AMPS) program will support research projects to develop the next generation of mathematical and statistical algorithms for improvement of the security, reliability, and efficiency of the modern power grid. The program is a partnership between the Division of Mathematical Sciences (DMS) at the National Science Foundation (NSF) and the Office of Electricity Delivery & Energy Reliability (OE) at the U.S. Department of Energy (DOE).
NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required)
Agency: National Institutes of Health
Posted: 2022-02-11 | Closing date: 2025-01-07
Cost sharing or matching requirement: No

The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to enhance the diversity of well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Guinea Local Health System Strengthening (GLHSS)
Agency: Guinea USAID-Conakry
Posted: 2022-02-16 | Closing date: 2025-02-25
Award ceiling: 0
Award floor: 0
Cost sharing or matching requirement: Yes

The U.S. Agency for International Development (USAID) Mission in Guinea is pleased to issue this APS for the implementation of an activity designed to strengthen local health systems in targeted geographic areas so that Guineans can access a higher quality of health care in their communities and local public health facilities. USAID/Guinea’s health office proposes the design of a new health sector activity entitled: Guinea Local Health System Strengthening (GLHSS). Its design involved USAID/Guinea, USAID/Washington, the Ministry of Health (MOH) and stakeholders working in the health sector. This co-engagement process will continue during the five-year implementation phase and will identify health topics on which additional information is needed.This APS document outlines the goal, purpose, expected results, and priorities of the Guinea Local Health System Strengthening (GLHSS), and may result in multiple awards issued under subsequent APS Rounds. GLHSS in this document is an umbrella APS and will not solicit concept papers or applications. Prospective applicants will be provided a fair opportunity to develop and submit competitive concept papers to USAID for potential funding via Rounds under this APS.
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-18 | Closing date: 2025-05-07
Award ceiling: 200000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-18 | Closing date: 2025-05-07
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. (link to OCCAM)

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-22 | Closing date: 2025-01-29
Cost sharing or matching requirement: No

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities thatcomplement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nations needs in biomedical research and healthcare technologies. Applications are encouraged from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets the education of undergraduate biomedical engineering/bioengineering students in a team-based environment. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Posted: 2022-02-22 | Closing date: 2024-06-13
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects validating approaches using other species are also permitted if well justified. Applications may address any aspects of the data collection, analysis, and dissemination pipelines, to enable faster and more cost-effective generation and interpretation of brain-wide wiring diagrams. Projects will offer distinct capabilities and competencies aimed at developing and optimizing current technologies or entirely new and potentially risky approaches. They will be integrated into the BRAIN CONNECTS Network, consisting of other Specialized Projects from this FOA, and Comprehensive Centers from its companion announcements, as a coordinated effort aimed at developing wiring diagrams that can span entire brains across multiple scales.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)
Agency: National Institutes of Health
Posted: 2022-02-23 | Closing date: 2024-12-10
Award ceiling: 75000
Cost sharing or matching requirement: No

This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
Agency: National Institutes of Health
Posted: 2022-02-23 | Closing date: 2025-05-07
Cost sharing or matching requirement: No

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Eligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.